OCALIVA
Total Payments
$91.2M
Transactions
85,584
Doctors
16,677
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.1M | 13,919 | 6,511 |
| 2023 | $14.3M | 17,349 | 6,902 |
| 2022 | $12.2M | 14,955 | 5,861 |
| 2021 | $11.2M | 12,243 | 4,693 |
| 2020 | $14.3M | 7,271 | 2,805 |
| 2019 | $15.1M | 9,769 | 3,634 |
| 2018 | $14.0M | 10,078 | 3,842 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $75.5M | 13,325 | 82.8% |
| Consulting Fee | $6.1M | 1,930 | 6.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3.1M | 1,204 | 3.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1.9M | 698 | 2.1% |
| Food and Beverage | $1.7M | 65,182 | 1.8% |
| Honoraria | $1.4M | 1,241 | 1.5% |
| Travel and Lodging | $634,158 | 1,683 | 0.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $591,872 | 15 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $155,150 | 21 | 0.2% |
| Grant | $62,300 | 19 | 0.1% |
| Education | $32,782 | 266 | 0.0% |
Payments by Type
Research
$75.5M
13,325 transactions
General
$15.6M
72,259 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 1011866 | Intercept Pharmaceuticals, Inc. | $31.8M | 3 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | Intercept Pharmaceuticals, Inc. | $20.0M | 4 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | Intercept Pharma Europe Ltd. | $9.9M | 3 |
| 1009742 | Intercept Pharmaceuticals, Inc. | $6.0M | 1 |
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) | Intercept Pharmaceuticals, Inc. | $3.1M | 0 |
| Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | INTERCEPT PHARMACEUTICALS, INC. | $1.5M | 19 |
| 1011866 | INTERCEPT PHARMACEUTICALS, INC. | $1.5M | 4 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC | Intercept Pharmaceuticals, Inc. | $369,956 | 4 |
| Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis (COBALT) | INTERCEPT PHARMACEUTICALS, INC. | $208,695 | 4 |
| Study Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC | Intercept Pharmaceuticals, Inc. | $203,607 | 0 |
| A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | Intercept Pharmaceuticals, Inc. | $178,298 | 0 |
| Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (REVERSE) | INTERCEPT PHARMACEUTICALS, INC. | $163,840 | 2 |
| 7001735 | Intercept Pharmaceuticals, Inc. | $151,952 | 0 |
| 1011507 | Intercept Pharmaceuticals, Inc. | $121,064 | 0 |
| Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Patients With PBC | INTERCEPT PHARMACEUTICALS, INC. | $107,214 | 0 |
| 1011386 | Intercept Pharmaceuticals, Inc. | $98,191 | 0 |
| 1012528 | Intercept Pharmaceuticals, Inc. | $94,684 | 0 |
| 1012528 | INTERCEPT PHARMACEUTICALS, INC. | $33,494 | 0 |
| Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems | Intercept Pharmaceuticals, Inc. | $20,000 | 0 |
| A Real-World Pilot Study of Transient Elastography Frequency and Liver Stiffness in Patients with PBC treated with OCA. This study is conducted using electronic health record data from patients diagnosed with PBC treated with OCA | Intercept Pharmaceuticals, Inc. | $10,000 | 0 |
Top Doctors Receiving Payments for OCALIVA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Nephrology | Bala Cynwyd, PA | $77,225 | 14 |
| , M.D | Internal Medicine | Houston, TX | $74,176 | 75 |
| , M.D | Internal Medicine | Flushing, NY | $73,630 | 84 |
| , M.D | Hepatology | Charlestown, MA | $72,566 | 2 |
| , M.D., M.H.S | Internal Medicine | Bala Cynwyd, PA | $72,032 | 22 |
| , MD | Gastroenterology | Orange, CA | $70,741 | 71 |
| , M.D | Internal Medicine | Los Angeles, CA | $70,147 | 12 |
| John Kostis | — | Bala Cynwyd, PA | $62,974 | 13 |
| , M.D | Gastroenterology | Bala Cynwyd, PA | $62,332 | 16 |
| , MD | Hepatology | New Orleans, LA | $60,104 | 45 |
| , M.D | Gastroenterology | Glendale, AZ | $58,785 | 76 |
| , MD | Gastroenterology | Hartford, CT | $58,744 | 68 |
| , M.D | Transplant Hepatology | Detroit, MI | $58,199 | 34 |
| , M.D | Hepatology | Houston, TX | $57,534 | 70 |
| , MD, MBA | Transplant Hepatology | Lakewood Ranch, FL | $57,454 | 47 |
| , MD | Internal Medicine | Charlotte, NC | $55,745 | 44 |
| , M.D | Transplant Hepatology | Salt Lake City, UT | $55,605 | 48 |
| , MD | Pediatric Gastroenterology | Memphis, TN | $55,400 | 21 |
| Victor Ankoma-Sey | — | Houston, TX | $55,115 | 109 |
| , MD | Transplant Hepatology | Valhalla, NY | $54,177 | 56 |
| , R.N | Nurse Practitioner | Lone Tree, CO | $53,302 | 108 |
| , M.D | Gastroenterology | New Orleans, LA | $52,662 | 57 |
| , M.D | Gastroenterology | Cincinnati, OH | $51,919 | 51 |
| , C.N.P | Adult Health | Canton, OH | $50,465 | 110 |
| , MD | Gastroenterology | Atlanta, GA | $49,162 | 99 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $91.2M
- Total Doctors 16,677
- Transactions 85,584
About OCALIVA
OCALIVA is a drug associated with $91.2M in payments to 16,677 healthcare providers, recorded across 85,584 transactions in the CMS Open Payments database. The primary manufacturer is Intercept Pharmaceuticals, Inc..
Payment data is available from 2018 to 2024. In 2024, $10.1M was paid across 13,919 transactions to 6,511 doctors.
The most common payment nature for OCALIVA is "Unspecified" ($75.5M, 82.8% of total).
OCALIVA is associated with 20 research studies, including "1011866" ($31.8M).